ArticleTherapeutic advances in neurological disorders2008
Recombinant Human Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis.
Article in Therapeutic advances in neurological disorders, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- From Erythropoiesis to Circuit Rewiring: Erythropoietin as a Precision Tool for Neurorestoration.International journal of molecular sciences · 2026Review
- Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues.Molecular medicine (Cambridge, Mass.) · 2021Review
- Erythropoietin as candidate for supportive treatment of severe COVID-19.Molecular medicine (Cambridge, Mass.) · 2020Review
- Cognitive interventions for adults with chronic kidney disease: protocol for a scoping review.Systematic reviews · 2020Article
- Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Review
- How to pursue EPO in MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2018Article
- Review
- Cross-talks between the kidneys and the central nervous system in multiple sclerosis.Caspian journal of internal medicine · 2018Review
- EV-3, an endogenous human erythropoietin isoform with distinct functional relevance.Scientific reports · 2017Article
- A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives.International journal of molecular sciences · 2016Review
- Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- A double-blind, placebo-controlled trial of adding erythropoietin to intravenous methylprednisolone for the treatment of unilateral acute optic neuritis of unknown or demyelinative origin.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015Article
- Erythropoietin: emerging role of erythropoietin in neonatal neuroprotection.Pediatric neurology · 2014Review
- A pilot study of the effect of intravenous erythropoetin on improvement of visual function in patients with recent indirect traumatic optic neuropathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2014Article
- Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.Acta neuropathologica communications · 2014Review
- Erythropoietin (EPO) increases myelin gene expression in CG4 oligodendrocyte cells through the classical EPO receptor.Molecular medicine (Cambridge, Mass.) · 2013Article
- Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice.Molecular medicine (Cambridge, Mass.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of multiple sclerosis (MS) is still unsatisfactory and essentially non-existing for the progressive course of the disease. Recombinant human erythropoietin (EPO) may be a promising neuroprotective/neuroregenerative treatment of MS. In the nervous system, EPO acts anti-apoptotic, antioxidative, anti-inflammatory, neurotrophic and plasticity-modulating. Beneficial effects have been shown in animal models of various neurological and psychiatric diseases, including different models of experimental autoimmune encephalomyelitis. EPO is also effective in human brain disease, as shown in double-blind placebo-controlled clinical studies on ischemic stroke and chronic schizophrenia. An exploratory study on chronic progressive MS yielded lasting improvement in motor and cognitive performance upon high-dose long-term EPO treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.